文献速递心脑血管急症重症综合管理与镇静镇痛

中性粒细胞-淋巴细胞比值与脑室内出血后30天感染及血栓结局的关联:CLEAR III分析

Association Between Neutrophil-Lymphocyte Ratio and 30-Day Infection and Thrombotic Outcomes After Intraventricular Hemorrhage: A CLEAR III Analysis.
PubMed 文献 · Neurocrit Care · 2023-06-22
一句话结论CLEAR III事后分析显示,基线及第3天中性粒细胞-淋巴细胞比值(NLR)与30天感染相关,第5天NLR与血栓事件相关。

该研究为CLEAR III试验的事后探索性分析,纳入303例(60.6%)基线白细胞分类数据完整的脑室内出血患者。暴露为基线及第3、5天血清NLR,共同主要终点为30天任何感染和血栓事件(脑梗死、心肌梗死或静脉血栓栓塞的复合终点),均经裁定不良事件报告确定。调整人口学、ICH严重程度与部位及治疗随机化后,基线NLR(OR 1.03;95%CI 1.01-1.07,p=0.03)和第3天NLR(OR 1.15;95%CI 1.05-1.20,p=0.001)与感染相关;第5天NLR与血栓事件相关(OR 1.07,95%CI 1.01-1.13,p=0.03)但与感染无关(OR 1.13;95%CI 0.76-1.70,p=0.56);基线NLR与两种结局均无关。作者认为NLR可能是ICH相关并发症的潜在早期生物标志物。

要点

  • CLEAR III事后分析纳入303例脑室内出血患者,基线NLR与30天感染相关(OR 1.03;95%CI 1.01-1.07,p=0.03)。
  • 第3天NLR与30天感染相关(OR 1.15;95%CI 1.05-1.20,p=0.001),但与血栓事件无关。
  • 第5天NLR与30天血栓事件相关(OR 1.07,95%CI 1.01-1.13,p=0.03),但与感染无关(OR 1.13;95%CI 0.76-1.70,p=0.56)。
  • 基线NLR与30天感染及血栓事件均无关。
  • 作者认为NLR可能是ICH相关并发症的潜在早期生物标志物。

适用人群与场景

  • CLEAR III试验纳入的脑室内出血患者,本分析纳入其中基线白细胞分类计数数据完整的303例(60.6%)。
  • 有与无NLR数据的患者在人口学、合并症或ICH严重程度方面无差异。

诊断标准与关键阈值

  • 暴露为基线及第3、5天采集的血清中性粒细胞-淋巴细胞比值(NLR)。
  • 共同主要终点为30天任何感染和血栓事件,血栓事件定义为脑梗死、心肌梗死或静脉血栓栓塞的复合终点,均经裁定不良事件报告确定。

研究设计与关键结果

  • 研究类型为CLEAR III试验的事后探索性分析,共纳入303例基线白细胞分类数据完整的脑室内出血患者。
  • 调整人口学、ICH严重程度与部位及治疗随机化后,基线NLR与30天感染相关(OR 1.03;95%CI 1.01-1.07,p=0.03),第3天NLR与30天感染相关(OR 1.15;95%CI 1.05-1.20,p=0.001)。
  • 第5天NLR与30天血栓事件相关(OR 1.07,95%CI 1.01-1.13,p=0.03),但与感染无关(OR 1.13;95%CI 0.76-1.70,p=0.56)。
  • 基线NLR与30天感染及血栓事件均无关。

证据类型、等级与局限

  • 证据类型:CLEAR III随机对照试验的事后探索性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为血清NLR可能是ICH相关并发症的潜在早期生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Serum neutrophil-lymphocyte ratio (NLR) is a surrogate marker for the inflammatory response after intracerebral hemorrhage (ICH) and is associated with perihematomal edema and long-term functional outcomes. Whether NLR is associated with short-term ICH complications is poorly understood. We hypothesized that NLR is associated with 30-day infection and thrombotic events after ICH.

METHODS: We performed a post hoc exploratory analysis of the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III trial. The study exposure was the serum NLR obtained at baseline and on days 3 and 5. The coprimary outcomes, ascertained at 30 days, were any infection and a thrombotic event, defined as composite of cerebral infarction, myocardial infarction, or venous thromboembolism; both infection and thrombotic event were determined through adjudicated adverse event reporting. Binary logistic regression was used to study the relationship between NLR and outcomes, after adjustment for demographics, ICH severity and location, and treatment randomization.

RESULTS: Among the 500 patients enrolled in the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage III trial, we included 303 (60.6%) without missing data on differential white blood cell counts at baseline. There were no differences in demographics, comorbidities, or ICH severity between patients with and without data on NLR. In adjusted logistic regression models, NLR ascertained at baseline (odds ratio [OR] 1.03; 95% confidence interval [CI] 1.01-1.07, p = 0.03) and NLR ascertained at day 3 were associated with infection (OR 1.15; 95% CI 1.05-1.20, p = 0.001) but not with thrombotic events. Conversely, NLR at day 5 was associated with thrombotic events (OR 1.07, 95% CI 1.01-1.13, p = 0.03) but not with infection (OR 1.13; 95% CI 0.76-1.70, p = 0.56). NLR at baseline was not associated with either outcome.

CONCLUSIONS: Serum NLR ascertained at baseline and on day 3 after randomization was associated with 30-day infection, whereas NLR obtained on day 5 was associated with thrombotic events after ICH, suggesting that NLR could be a potential early biomarker for ICH-related complications.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Kaleem S, Zhang C, Gusdon AM, et al. Association Between Neutrophil-Lymphocyte Ratio and 30-Day Infection and Thrombotic Outcomes After Intraventricular Hemorrhage: A CLEAR III Analysis. Neurocrit Care. 2023. PMID: 37349600. doi:10.1007/s12028-023-01774-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。